aTyr Pharma Shareholders Approve 1-for-10 to 1-for-50 Reverse Split

summarizeSummary

aTyr Pharma shareholders approved a reverse stock split at a ratio between 1-for-10 and 1-for-50, giving the board authority to execute the split to regain Nasdaq compliance. The vote passed with 52.5 million shares in favor against 5.2 million opposed.

check_boxKey Events · Corporate Governance and Compliance · ATYR

• Reverse Split Approved by Shareholders

  Proposal 1 passed with 52,451,734 votes for, 5,234,645 against, and 228,991 abstentions, authorizing the board to effect a reverse split at a ratio between 1-for-10 and 1-for-50.

• Board Gains Discretion on Timing and Ratio

  The board may execute the split at any ratio within the approved range at its sole discretion; no specific ratio or effective date was disclosed in this filing.

• Nasdaq Compliance at Stake

  The stock trades at $0.174, well below Nasdaq's $1.00 minimum bid price requirement; the reverse split is intended to restore compliance and avoid delisting.

• Context: 60% Workforce Cut and Executive Departures

  The vote follows the August 2026 announcement of a 60% workforce reduction and the departures of the CFO and General Counsel as the company pivots to a Phase 3 efzofitimod program.

auto_awesomeAnalysis · ATYR · Life Sciences

Shareholders approved the board's authority to execute a reverse split at a ratio between 1-for-10 and 1-for-50, clearing the final hurdle to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The stock trades at $0.174, far below the threshold, and the company has already cut 60% of its workforce and lost its CFO and General Counsel as it pivots to a Phase 3 efzofitimod program. The board now has discretion on timing and ratio; the split will mechanically lift the share price but does not change the underlying cash burn or the need for additional capital.